TAP Prevacid maintenance of healed erosive esophagitis indication approved April 8.
Executive Summary
TAP PREVACID MAINTENANCE OF HEALED EROSIVE ESOPHAGITIS INDICATION APPROVED by FDA April 8. The proton pump inhibitor lansaprazole has a recommended daily dose of 15 mg for the new indication. The delayed-release capsule PPI from the joint venture Takeda-Abbott Pharmaceuticals originally was approved May 10, 1995 for short-term treatment for healing and symptom relief of active duodenal ulcer and erosive esophagitis and for long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome ("The Pink Sheet" May 15, 1995, p. 3).